Competition Twists Line Between Marketing Drugs, Cosmetics – Attorney
This article was originally published in The Tan Sheet
Executive Summary
The line dividing drugs from personal care products is "fuzzy," but assessing the mistakes of other firms is a clear way to understand what marketing claims FDA will accept, according to attorney Ivan Wasserman
You may also be interested in...
Unsubstantiated Claims Come In Many Forms, Create Minefield Of Challenges
Supplement firms should not expect a product claim to be acceptable to FDA "just because other people are saying it" and should acknowledge that "just because it's natural doesn't mean it's safe," industry consultant Ivan Wasserman advises
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands